As effective as new gene therapy treatments may be, high setup costs, variable clinical responses, and issues with reimbursement and coding have resulted in significant losses for some manufacturers and providers. “The one-time administration for these therapies introduces a mismatch with benefits” said Jane F. Barlow, Real Endpoints Chief Clinical Officer. “The cost is front-loaded, but benefits accrue over time, creating a challenge as patients move in and out of plans. This is very different than what we see with chronic medications.”
read full article ›